

AGENDA - Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer - Houston, TX – April 3-4, 2015

LUNG CANCER - FRIDAY – April 3, 2015

7:00 AM	Continental Breakfast and Registrations	
7:55 AM	Welcome and Introductions	John Heymach, MD, PhD
	Keynote Lectures	
8:30 AM	Primacy of Staging and Histology in the Treatment of NSCLC	
9:00 AM	Questions	TBD
9:05 AM	Molecular Profiling in the Treatment of NSCLC	John V. Heymach, MD, PhD
9:35 AM	Questions	
9:40 AM	EGFR and ALK Inhibitors for NSCLC	George R. Blumenschein, Jr., MD
10:10 AM	Questions	
10:15 AM	Panel Discussion #1 Interactive Case Study	TBD/John V. Heymach, MD, PhD/George R. Blumenschein, Jr., MD
10:30 AM	BREAK	
	Radiation Therapy and Clinical Trial Forums	
10:40 AM	Current ECOG, CALGB and SWOG Clinical Trials	Vassiliki Papadimitrakopoulou, MD
11:10 AM	Questions	
11:15 AM	Update on Radiation Therapy Options for Lung Cancer	Hak Choy, MD
11:45 AM	Questions	
11:50 PM	Panel Discussion #2 Interactive Case Study	Vassiliki Papadimitrakopoulou, MD/Hak Choy, MD
	Targeted Therapies	
12:05 PM	Maintenance Therapy for NSCLC: Is this Now Standard?	
12:35 PM	Questions	David Gerber, MD
12:40 PM	LUNCH	
1:25 PM	KRAS and PARP Inhibitors for NSCLC	John Heymach, MD, PhD
1:55 PM	Questions	
2:00 PM	Adjuvant Therapy for NSCLC: Consensus and Controversies	
2:30 PM	Questions	TBD
2:35 PM	BREAK	
2:45 PM	Harnessing Immune System for the Treatment of NSCLC	Donald L. Gibbons, MD
3:15 PM	Questions	
3:20 PM	Panel Discussion #3 Interactive Case Study	David Gerber, MD/TBD/TBD
3:35 PM	Defining the Economic Value of New Lung and Breast	James Koeller, MA

4:05 PM	Cancer Therapies Questions	
4:10 PM	Closing Remarks and Adjourn	John Heymach, MD, PhD
BREAST CANCER - SATURDAY – April 4, 2015		
7:00 AM	Continental Breakfast	
7:55 AM	Opening Remarks	Mark Pegram, MD
	Novel Therapies of Breast Cancer	
8:30 AM	State of the Art: Breast Cancer Therapy 2014	Vicente Valero, MD
9:00 AM	Questions	
9:05 AM	Advances in the treatment options for patients with HER2- positive metastatic breast cancer	Mark Pegram, MD
9:35 AM	Questions	
9:40 AM	Optimizing Adjuvant Hormonal Therapy in Breast Cancer: Current Status	Mark Pegram, MD
10:10 AM	Questions	
10:15 AM	Panel Discussion#4 and Case Presentation	Vicente Valero, MD/ Mark Pegram, MD
10:30 AM	BREAK	
10:40 AM	Comprehensive Genomic Analysis: Identification of Subtypes and Novel Targets for Triple-negative Breast Cancer	Stacy Moulder, MD
11:10 AM	Questions	
11:15 AM	Role of mTOR Inhibitors in the Treatment of Endocrine-sensitive Metastatic Breast Cancer	Mariana Chavez-MacGregor, MD
11:45 AM	Questions	
11:50 AM	Therapeutic Strategies Directed at Prevention and Management of Bone Metastasis in Women with Breast Cancer	Naoto Ueno, MD
12:20 PM	Questions	
12:25 AM	Panel Discussion#5 and Case Presentation	Stacy Moulder, MD/ Mariana Chavez-MacGregor, MD/Naoto Ueno, MD
12:40 PM	LUNCH	
	Molecular Subtypes and Markers in Breast Cancer	
1:25 PM	Genetic Counseling and Management of Breast Cancer in BRCA Carriers: Role of New Approaches in Testing	Mariana Chavez-MacGregor, MD
1:55 PM	Questions	
2:00 PM	Predictive and Prognostic Markers for Response and Survival in Breast Cancer	Merrick Ross, MD
2:30 PM	Questions	
2:35PM	BREAK	
2:45 PM	Treatment Insights Based on Molecular Subtypes and Novel Diagnostics: Endopredict vs Oncotype RS	TBD

3:15 PM	Questions	
3:20 PM	Panel Discussion#6 and Case Presentation	Mariana Chavez-MacGregor, MD/TBD/TBD
	Radiation Therapy Approaches in Breast Cancer	
3:35 PM	New Insights into Optimizing Local-regional Control in Breast Cancer: Personalizing Therapy	Eric A. Strom, MD
4:05 PM	Questions	
4:10 PM	Closing Remarks and Adjourn	Mark Pegram, MD